| 1 |
Immunolocalization of calpain I-mediated spectrin degradation to vulnerable neurons in the ischemic gerbil brain
JM Roberts-Lewis, MJ Savage, VR Marcy et al. · Journal of Neuroscience
Open access |
Jun 1994 |
322 |
| 2 |
VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-β-Lactamases, Restores Activity of Cefepime in Enterobacterales and Pseudomonas aeruginosa
Jodie C. Hamrick et al. · Antimicrobial Agents and Chemotherapy
Open access |
18 Dec 2019 |
220 |
| 3 |
Iron Acquisition Systems of Gram-negative Bacterial Pathogens Define TonB-Dependent Pathways to Novel Antibiotics
Phillip E. Klebba, Salete M. Newton, David A. Six et al. · Chemical Reviews
ReviewOpen access |
16 Mar 2021 |
153 |
| 4 |
Recent Advances in Amorphous Solid Dispersions: Preformulation, Formulation Strategies, Technological Advancements and Characterization
Srushti M. Tambe, Divya D. Jain, Saikishore Meruva et al. · Pharmaceutics
Open access |
16 Oct 2022 |
127 |
| 5 |
International Union of Basic and Clinical Pharmacology. XCII. Urotensin II, Urotensin II–Related Peptide, and Their Receptor: From Structure to Function
Hubert Vaudry, Jérôme Leprince, David Chatenet et al. · Pharmacological Reviews
Open access |
23 Dec 2014 |
106 |
| 6 |
Substituted 1,2-Dihydrophthalazines: Potent, Selective, and Noncompetitive Inhibitors of the AMPA Receptor
Jeffrey C. Pelletier, David P. Hesson, KENNETH ARTHUR JONES et al. · Journal of Medicinal Chemistry
|
1996 |
94 |
| 7 |
Desensitization of Kainate Receptors by Kainate, Glutamate and Diastereomers of 4-Methylglutamate
KENNETH ARTHUR JONES, Timothy J. Wilding, James E. Huettner et al. · Neuropharmacology
|
Jun 1997 |
83 |
| 8 |
In Vitro Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program
James A. Karlowsky, Meredith Hackel, Mark G G Wise et al. · Antimicrobial Agents and Chemotherapy
Open access |
21 Dec 2022 |
73 |
| 9 |
Cloning of the cDNA for the human NMDA receptor NR2C subunit and its expression in the central nervous system and periphery
Yuzhong J. Lin, Sylvie Bovetto, Jeffrey M. Carver et al. · Molecular Brain Research
|
Dec 1996 |
55 |
| 10 |
Discovery of VNRX-7145 (VNRX-5236 Etzadroxil): An Orally Bioavailable β-Lactamase Inhibitor for Enterobacterales Expressing Ambler Class A, C, and D Enzymes
Robert E. Lee Trout, Allison L. Zulli, Eugen F. Mesaros et al. · Journal of Medicinal Chemistry
Open access |
30 Jun 2021 |
48 |
| 11 |
Granzyme B Expression Is Enhanced in Human Monocytes by TLR8 Agonists and Contributes to Antibody-Dependent Cellular Cytotoxicity
Saranya Elavazhagan, Kavin Fatehchand, Vikram Santhanam et al. · The Journal of Immunology
Open access |
10 Feb 2015 |
42 |
| 12 |
Safety and Pharmacokinetics in Human Volunteers of Taniborbactam (VNRX-5133), a Novel Intravenous β-Lactamase Inhibitor
James A. Dowell, Daniel Dickerson, Tim Henkel · Antimicrobial Agents and Chemotherapy
Open access |
9 Aug 2021 |
37 |
| 13 |
Differential effects of agents acting at various sites of the NMDA receptor complex in a place preference conditioning model
Mariusz Papp, Elżbieta Moryl, Maria‐Luisa Maccecchini · European Journal of Pharmacology
|
Dec 1996 |
36 |
| 14 |
Microbiological Characterization of VNRX-5236, a Broad-Spectrum β-Lactamase Inhibitor for Rescue of the Orally Bioavailable Cephalosporin Ceftibuten as a Carbapenem-Sparing Agent against Strains of Enterobacterales Expressing Extended-Spectrum β-Lactamases and Serine Carbapenemases
Cassandra L. Chatwin, Jodie C. Hamrick, Robert E. Lee Trout et al. · Antimicrobial Agents and Chemotherapy
Open access |
17 May 2021 |
35 |
| 15 |
1 ‐Aminocyclopropanecarboxylic Acid: Mouse to Man lnterspecies Pharmacokinetic Comparisons and Allometric Relationships
Saul C. Cherkofsky · Journal of Pharmaceutical Sciences
|
Oct 1995 |
35 |
| 16 |
Safety and Pharmacokinetics of Taniborbactam (VNRX-5133) with Cefepime in Subjects with Various Degrees of Renal Impairment
James A. Dowell, Thomas C Marbury, William Burton Smith et al. · Antimicrobial Agents and Chemotherapy
Open access |
3 Aug 2022 |
33 |
| 17 |
Fluorescent sensors of siderophores produced by bacterial pathogens
Ashish Kumar, Taihao Yang, Somnath Chakravorty et al. · Journal of Biological Chemistry
Open access |
29 Jan 2022 |
30 |
| 18 |
Characterization of Poliovirus Variants Selected for Resistance to the Antiviral Compound V-073
Hongmei Liu, Jason Alexander Roberts, Deborah D. Moore et al. · Antimicrobial Agents and Chemotherapy
Open access |
13 Aug 2012 |
30 |
| 19 |
Cefepime–taniborbactam activity against antimicrobial-resistant clinical isolates of Enterobacterales and Pseudomonas aeruginosa : GEARS global surveillance programme 2018–22
James A. Karlowsky, Mark G G Wise, Meredith Hackel et al. · Journal of Antimicrobial Chemotherapy
Open access |
3 Sep 2024 |
26 |
| 20 |
The discovery and structure–activity relationships of pyrano[3,4-b]indole-based inhibitors of hepatitis C virus NS5B polymerase
Randy W. Jackson, Matthew G. LaPorte, Torsten Herbertz et al. · Bioorganic & Medicinal Chemistry Letters
|
24 Apr 2011 |
23 |
| 21 |
Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection
Greg Moeck, Leanne B. Gasink, Rodrigo Elisandro Mendes et al. · Antimicrobial Agents and Chemotherapy
Open access |
23 May 2024 |
22 |
| 22 |
Ceftibuten-Ledaborbactam Activity against Multidrug-Resistant and Extended-Spectrum-β-Lactamase-Positive Clinical Isolates of Enterobacterales from a 2018–2020 Global Surveillance Collection
James A. Karlowsky, Mark G G Wise, Meredith Hackel et al. · Antimicrobial Agents and Chemotherapy
Open access |
26 Oct 2022 |
20 |
| 23 |
1370. Cefepime/VNRX-5133 Broad-Spectrum Activity Is Maintained Against Emerging KPC- and PDC-Variants in Multidrug-Resistant K. pneumoniae and P. aeruginosa
Denis M. Daigle, Jodie C. Hamrick, Cassandra L. Chatwin et al. · Open Forum Infectious Diseases
Open access |
Nov 2018 |
18 |
| 24 |
The Next-Generation β-Lactamase Inhibitor Taniborbactam Restores the Morphological Effects of Cefepime in KPC-Producing Escherichia coli
Elyse J. Roach, Tsuyoshi Uehara, Denis M. Daigle et al. · Microbiology Spectrum
Open access |
8 Sep 2021 |
16 |
| 25 |
Historical perspective of chemical warfare agents
Nathan H. Johnson, Joseph C. Larsen, Edward C. Meek · Elsevier eBooks
Book chapter |
2020 |
15 |
| 26 |
ARGONAUT-III and -V: susceptibility of carbapenem-resistant Klebsiella pneumoniae and multidrug-resistant Pseudomonas aeruginosa to the bicyclic boronate β-lactamase inhibitor taniborbactam combined with cefepime
Michael R. Jacobs, Ayman M. Abdelhamed, Caryn E. Good et al. · Antimicrobial Agents and Chemotherapy
Open access |
12 Aug 2024 |
14 |
| 27 |
In vivo pharmacokinetics and pharmacodynamics of ceftibuten/ledaborbactam, a novel oral β-lactam/β-lactamase inhibitor combination
Andrew J Fratoni, Lindsay M. Avery, David P Nicolau et al. · Journal of Antimicrobial Chemotherapy
Open access |
6 Oct 2022 |
13 |
| 28 |
731. CERTAIN-1: A Phase 3 Study of Cefepime-Taniborbactam Efficacy and Safety in the Treatment of Complicated Urinary Tract Infections (cUTI), including Acute Pyelonephritis (AP)
Paul C. McGovern, Florian Wagenlehner, Leanne B. Gasink et al. · Open Forum Infectious Diseases
Open access |
Dec 2022 |
12 |
| 29 |
Cefepime–taniborbactam and ceftibuten–ledaborbactam maintain activity against KPC variants that lead to ceftazidime–avibactam resistance
Cullen L. Myers, Annie Stevenson, Brittany Miller et al. · Antimicrobial Agents and Chemotherapy
Open access |
10 Feb 2025 |
11 |
| 30 |
Motolimod effectively drives immune activation in advanced cancer patients
Gregory N. Dietsch · OncoImmunology
Open access |
9 Feb 2016 |
11 |
| 31 |
Thrombosis of parietal, but not striate, cortex impairs acquisition of a 14-unit T-maze in the rat
Edward L. Spangler, Brett Heller, John M. Hengemihle et al. · Physiology & Behavior
|
Jul 1994 |
11 |
| 32 |
Spectrum of cefepime-taniborbactam coverage against 190 β-lactamases defined in engineered isogenic Escherichia coli strains
Tsuyoshi Uehara, Cassandra L. Chatwin, Brittany Miller et al. · Antimicrobial Agents and Chemotherapy
Open access |
Apr 2025 |
7 |
| 33 |
Impact of porin deletions on cefepime-taniborbactam activity against Klebsiella pneumoniae
Tsuyoshi Uehara, Cassandra L. Chatwin, Brittany Miller et al. · Antimicrobial Agents and Chemotherapy
Open access |
2 Apr 2025 |
6 |
| 34 |
ARGONAUT-IV: susceptibility of carbapenemase-producing Klebsiella pneumoniae to the oral bicyclic boronate β-lactamase inhibitor ledaborbactam combined with ceftibuten
Michael R. Jacobs, Caryn E. Good, Ayman M. Abdelhamed et al. · Antimicrobial Agents and Chemotherapy
Open access |
30 Oct 2024 |
6 |
| 35 |
Cefepime-taniborbactam demonstrates potent in vitro activity vs Enterobacterales with bla OXA-48
María Fernanda Mojica, Elise T. Zeiser, Scott A. Becka et al. · Microbiology Spectrum
Open access |
24 Sep 2024 |
6 |
| 36 |
Examining the activity of cefepime-taniborbactam against Burkholderia cepacia complex and Burkholderia gladioli isolated from cystic fibrosis patients in the United States
María Fernanda Mojica, Elise T. Zeiser, Scott A. Becka et al. · Antimicrobial Agents and Chemotherapy
Open access |
28 Sep 2023 |
6 |
| 37 |
Cytotoxic effects of kainate ligands on HEK cell lines expressing recombinant kainate receptors
Jeffrey M. Carver, Per‐Erik Mansson, Luz A. Cortes-Burgos et al. · Brain Research
Open access |
May 1996 |
6 |
| 38 |
Diastereoselective synthesis of (2S,4R)-4-Methylglutamic acid (sym 2081): A high affinity and selective ligand at the kainate subtype of glutamate receptors
Zi‐Qiang Gu, Xiao‐Fa Lin, David P. Hesson · Bioorganic & Medicinal Chemistry Letters
|
Sep 1995 |
6 |
| 39 |
Establishing the reference broth microdilution MIC method for cefepime-taniborbactam
Adam C. Belley, Susan M. Cusick, Dan C. Pevear et al. · Journal of Clinical Microbiology
Open access |
19 Aug 2025 |
4 |
| 40 |
Pharmacokinetics and safety of single and repeat doses of ceftibuten in healthy participants: a phase 1 dose escalation study
Mary Beth Dorr, Carlos Fernando de Oliveira, Jeroen van de Wetering et al. · Antimicrobial Agents and Chemotherapy
Open access |
14 Aug 2025 |
4 |
| 41 |
Plasma and intrapulmonary pharmacokinetics of cefepime and taniborbactam in healthy adult participants
Keith A. Rodvold, Mark H. Gotfried, Philip E. Sabato et al. · Antimicrobial Agents and Chemotherapy
Open access |
6 Jun 2025 |
4 |
| 42 |
Cefepime–Taniborbactam in Complicated Urinary Tract Infection
Simone Lanini, Tommaso Cai, Carlo Tascini · New England Journal of Medicine
|
29 May 2024 |
4 |
| 43 |
Metabolic Incorporation of Azido-Sugars into LPS to Enable Live-Cell Fluorescence Imaging
Inga Marie Nilsson, David A. Six · Methods in molecular biology
Book chapter |
2022 |
4 |
| 44 |
Assessment of human exposures of cefepime-taniborbactam against cefepime-resistant Enterobacterales and Pseudomonas aeruginosa in a 7-day hollow fiber infection model
Lindsay M. Avery, Mitchell Edwards, Fan Yi et al. · Antimicrobial Agents and Chemotherapy
Open access |
31 Jul 2025 |
3 |
| 45 |
2523. Outcomes by Resistance Phenotype and Genotype among Baseline Pathogen in Patients with Complicated Urinary Tract Infection (cUTI) in the Phase 3 CERTAIN-1 Study
Greg Moeck, Leanne B. Gasink, Mary Beth Dorr et al. · Open Forum Infectious Diseases
Open access |
27 Nov 2023 |
3 |
| 46 |
Gas chromatographic-mass spectrometric determination of urinary 1-aminocyclopropanecarboxylic acid in mice using a deuterated internal standard
Sharon E. Howell, Scott R. Miller, J. David McCallister et al. · Journal of Chromatography B Biomedical Sciences and Applications
|
1995 |
3 |
| 47 |
Development of ACPC, A Partial Agonist of the Glycine Site on the NMDA Receptor
Maria‐Luisa Maccecchini · Elsevier eBooks
Book chapter |
1997 |
3 |
| 48 |
In vivo activity of ceftibuten-ledaborbactam oral combination against serine-β-lactamase-producing Enterobacterales: an assessment in the pyelonephritis and cystitis murine model
Christina Koenig, Fan Yi, David P Nicolau et al. · Journal of Antimicrobial Chemotherapy
|
7 Aug 2025 |
2 |
| 49 |
Safety and pharmacokinetics of single and multiple doses of ledaborbactam etzadroxil with or without ceftibuten in healthy volunteers
Carlos Fernando de Oliveira, Mary Beth Dorr, Jeroen van de Wetering et al. · Antimicrobial Agents and Chemotherapy
Open access |
14 Aug 2025 |
2 |
| 50 |
Structure and mechanism of taniborbactam inhibition of the cefepime-hydrolyzing, partial R2-loop deletion Pseudomonas -derived cephalosporinase variant PDC-88
Andrew R Mack, Vijay Kumar, Christopher R. Bethel et al. · Antimicrobial Agents and Chemotherapy
Open access |
12 Jun 2025 |
2 |